skip to content

Early Cancer Institute



  • Assistant Professor and Group Leader, Department of Oncology, University of Cambridge
  • Co-Lead, Cancer Research UK Cambridge Centre - Ovarian Cancer Programme
  • Co-Lead, Cancer Research UK Cambridge Centre - Mark Foundation Institute for Integrated Cancer Medicine
  • Chief Digital Officer, 52North Health


Dr Mireia Crispin is an Assistant Professor in the Department of Oncology at the University of Cambridge, and leads a research group focusing on the development of multi-omic data integration models to understand response cancer therapies. She co-leads the Ovarian Programme at the CRUK Cancer Centre, and the Mark Foundation Institute for Integrated Cancer Medicine. She is also the Chief Digital Officer of 52 North Health, an award-winning biotech start-up developing affordable at-home tests for cancer patients. Dr Crispin worked previously at Memorial Sloan Kettering Cancer Center in New York, and was the Director of the Healthcare Innovation programme of the Center for the Governance of Change at IE University (Madrid, Spain), focusing on policy challenges for the integration of AI and digital health in European healthcare. She holds a PhD in Particle Physics (University of Oxford, 2015). She is an author in over 400 publications and has received numerous national and international awards, most recently finalist of the Cancer Research Horizons Early-Career Entrepreneur of the Year 2022 award.


Predictive modelling
The Crispin Group develops machine learning models based on imaging and other types of data to predict how cancer patients will respond to treatment.

Data integration
The group develops new technologies to spatially integrate multi-scale cancer data and unveil heterogeneity patterns.

Policy and engagement
Mireia's group contributes to the debate on the challenges and consequences of the development of artificial intelligence and digital health.

More details on research projects can be found at: